BioSpace News Archive

Akebia Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, granted three newly-hired employees options to purchase an aggregate of 15,600 shares of Akebia’s common stock on February 28, 2020, as inducements material to each such employee’s entering into employment with Akebia.

Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the year ended December 31, 2019. “

Bristol-Myers Squibb Company (NYSE:BMY) today declared a quarterly dividend of forty-five cents ($0.45) per share on the $.10 par value Common Stock of the corporation.

X4 Pharmaceuticals, Inc. announced that, on February 28, 2020, the Compensation Committee of X4’s Board of Directors issued an inducement award to a new employee under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan.

Tilray, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY), a global pioneer in cannabis production, research, cultivation and distribution, reports financial results for the fourth quarter and full fiscal year ended December 31, 2019.

Exelixis, Inc. (Nasdaq: EXEL) today announced that George A. Scangos, Ph.D. has notified the company of his decision to retire from the Exelixis Board of Directors.

Vivek Jayaraman promoted to Chief Operating Officer Dr. Nina Mufti promoted to VP Development and Red Blood Cell Program Leader Dr. Yasmin Singh promoted to VP Development and Platelet/Plasma/Therapeutics Program Leader

Natus Medical Incorporated (NASDAQ:NTUS) (the “Company” or “Natus”), today announced an update to its previously announced financial results for the three months and full year ended December 31, 2019.

Maxar Technologies (NYSE:MAXR) (TSX:MAXR) (“Maxar” or the “Company”), a trusted partner and innovator in Earth Intelligence and Space Infrastructure, today announced financial results for the quarter and year ended December 31, 2019.

Kane Biotech Inc. (TSX-V:KNE) (the “Company” or “Kane Biotech”) today announces that it granted an aggregate of 3,650,000 stock options (the “Options”) to certain directors, officers, employees and consultants of the Company in accordance with the Company’s stock option plan.